CRISPR Therapeutics Earnings Perspective: Return On Capital Employed
Portfolio Pulse from Benzinga Insights
CRISPR Therapeutics (NASDAQ:CRSP) reported Q1 sales of $100 million and a loss of $53.06 million, with earnings up 52.01%. The company posted a negative Return on Capital Employed (ROCE) of -0.03%, suggesting inefficient capital allocation. Q1 earnings per share were $-0.67, beating analyst predictions of $-1.7.
May 23, 2023 | 2:52 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
CRISPR Therapeutics reported Q1 sales of $100 million and a loss of $53.06 million. The company's negative ROCE of -0.03% suggests inefficient capital allocation, but earnings per share beat analyst predictions.
CRISPR Therapeutics' Q1 earnings show mixed results. While sales and earnings per share beat expectations, the negative ROCE indicates inefficient capital allocation. This could lead to neutral short-term price movement as investors weigh the positives and negatives.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100